Quipt Home Medical (QIPT) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Quipt Home Medical (QIPT – Research Report) today and set a price target of C$6.70. The company’s shares closed last Thursday at C$4.13.

Light Up your Portfolio with Spark:

• Easily identify stocks' risks and opportunities.
• Discover stocks' market position with detailed competitor analyses.

Keywood covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, Andlauer Healthcare Group, and Cipher Pharmaceuticals. According to TipRanks, Keywood has an average return of -8.5% and a 37.50% success rate on recommended stocks.

Currently, the analyst consensus on Quipt Home Medical is a Moderate Buy with an average price target of C$6.21, implying a 50.36% upside from current levels. In a report released on March 24, Canaccord Genuity also maintained a Buy rating on the stock with a $4.00 price target.

QIPT market cap is currently C$141.3M and has a P/E ratio of -15.50.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of QIPT in relation to earlier this year.